Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breas

[News]

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

More... (http://www.news-medical.net/news/20121211/Merrimack-announces-results-from-MM-302-Phase-I-trial-on-advanced-HER2-positive-breast-cancer.aspx)

[chrisy]

I was on this study. Didn't work for me, which was a bummer for many reasons, but not least of all because it was very easy to tolerate! And it did work for a lot of folks. Could be a great new weapon for the arsenals.